Latest news and articles about Order No. 818
Total: 1 articles found
China's implementation of Order No. 818 has forced the stem cell anti-aging industry into a secretive, high-priced grey market. Despite strict bans on charging for clinical trials, businesses are exploiting off-label drugs and private networks to meet the insatiable demand for longevity treatments among the elite.
